Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors
Summary : OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE), today announced that early biomarker analyses from the ongoing Phase 1 clinical trial with SIRPα…